Life Science Investing Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis
Life Science Investing Spero Therapeutics Announces Third Quarter 2025 Operating Results and Provides a Business Update
Life Science Investing Spero Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 13, 2025
Blackrock Silver Closes C$15 Million Private Placement Led By a C$7 Million Investment from Eric Sprott
Surface Sampling at Smart Creek Project Yields High-Grade Mineralization with up to 102 g/t Au, up to 23% Cu and up to 3810 g/t Ag
